TGFbDNRII-transduced Autologous Tumor Infiltrating Lymphocytes

BIOLOGICAL2 trials

Sponsors

M.D. Anderson Cancer Center, Roswell Park Cancer Institute

Conditions

Advanced Fallopian Tube CarcinomaAdvanced Malignant Solid NeoplasmAdvanced MelanomaAdvanced Ovarian CarcinomaAdvanced Primary Peritoneal CarcinomaAdvanced Synovial SarcomaClinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8

Phase 1

Genetically Modified T-Cells Followed by Aldesleukin in Treating Patients With Stage III-IV Melanoma

Active, not recruitingNCT01955460

M.D. Anderson Cancer CenterMetastatic Melanoma, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7 +3

Start: 2014-10-15End: 2027-10-30Target: 34Updated: 2026-04-15

Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1

Active, not recruitingNCT02650986

Roswell Park Cancer InstituteAdvanced Fallopian Tube Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Melanoma +47

Start: 2017-07-14End: 2032-07-14Updated: 2026-07-08

Related Papers

Recent Advancements in Cell-Based Therapies in Melanoma.

2024-09-124 citations

340 TGFβDNRII genetically-engineered TIL: characterizing final drug product from a phase I clinical trial

Regular and Young Investigator Award Abstracts2023-10-31

CRISPR-mediated TGFBR2 knockout renders human ovarian cancer tumor-infiltrating lymphocytes resistant to TGF-β signaling

Journal for ImmunoTherapy of Cancer2022-07-0138 citations

172 Overcoming immunosuppressive TGF-β signaling in human ovarian cancer-derived tumor infiltrating lymphocytes via non-viral CRISPR engineering

Regular and Young Investigator Award Abstracts2021-11-011 citations